Medicare tests extra drug rebates tied to prices in other wealthy countries
Makers of certain high-spending brand-name Medicare Part B drugs must pay added rebates when U.S. prices top a benchmark drawn from 19 other countries, for patients in the test areas. About a quarter of traditional Medicare patients, picked by ZIP code, pay lower coinsurance on those drugs.
Who it affects
Drug makers, and traditional Medicare patients in selected areas
When
The changes described here start on April 1, 2027.
- : Published in the Federal Register
- : The rule takes effect
- : Drug makers may start submitting international price data
- : The changes described here start to apply
- : The last performance year ends
Official text
FR Doc. 2026-20281: Global Benchmark for Efficient Drug Pricing (GLOBE) Model
On Federal Register. The official text is what counts; read it before you act.
Not legal advice. Plain-English summaries to help you find what changes and when. Not legal advice: read the official text, and ask a lawyer about your situation.